Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
May 14 04:00PM ET
14.60
Dollar change
+0.42
Percentage change
2.96
%
IndexRUT P/E12.00 EPS (ttm)1.22 Insider Own4.00% Shs Outstand57.33M Perf Week38.39%
Market Cap841.98M Forward P/E6.46 EPS next Y2.26 Insider Trans0.09% Shs Float55.36M Perf Month37.87%
Income70.20M PEG- EPS next Q0.46 Inst Own93.97% Short Float4.80% Perf Quarter2.46%
Sales1.13B P/S0.74 EPS this Y-23.91% Inst Trans-2.10% Short Ratio6.08 Perf Half Y-1.42%
Book/sh-13.35 P/B- EPS next Y-0.66% ROA5.83% Short Interest2.66M Perf Year-52.43%
Cash/sh5.31 P/C2.75 EPS next 5Y- ROE- 52W Range9.93 - 30.80 Perf YTD-22.87%
Dividend Est.0.57 (3.92%) P/FCF89.57 EPS past 5Y- ROI8.10% 52W High-52.60% Beta0.98
Dividend TTM0.60 (4.11%) Quick Ratio1.79 Sales past 5Y0.35% Gross Margin65.47% 52W Low47.10% ATR (14)0.74
Dividend Ex-DateMay 28, 2024 Current Ratio2.29 EPS Y/Y TTM-25.47% Oper. Margin20.17% RSI (14)74.99 Volatility7.13% 4.24%
Employees2200 Debt/Eq- Sales Y/Y TTM1.25% Profit Margin6.20% Recom3.75 Target Price15.00
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q105.38% Payout49.22% Rel Volume1.12 Prev Close14.18
Sales Surprise8.50% EPS Surprise67.50% Sales Q/Q3.64% EarningsMay 09 BMO Avg Volume437.46K Price14.60
SMA2032.95% SMA5021.00% SMA200-7.04% Trades Volume490,915 Change2.96%
Date Action Analyst Rating Change Price Target Change
Oct-20-23Initiated Wolfe Research Peer Perform
Jan-06-23Downgrade Morgan Stanley Equal-Weight → Underweight $28
Sep-08-22Initiated BTIG Research Neutral
Aug-01-22Initiated Morgan Stanley Equal-Weight $33
Jun-21-22Initiated BofA Securities Underperform $25
May-13-24 11:52AM
May-10-24 02:12PM
May-09-24 10:54AM
06:30AM
06:00AM
05:00PM Loading…
May-01-24 05:00PM
Apr-23-24 05:00PM
Mar-06-24 06:00AM
Feb-10-24 08:55AM
Feb-09-24 10:07PM
11:43AM
07:45AM
07:07AM
06:30AM
06:00AM
05:00PM Loading…
Feb-07-24 05:00PM
Jan-24-24 05:00PM
Jan-21-24 08:33AM
Jan-09-24 06:00AM
Dec-14-23 05:00PM
Dec-01-23 06:00AM
05:13AM
Nov-29-23 05:00PM
Nov-22-23 09:34AM
Nov-21-23 07:23AM
07:15AM
07:13AM
05:30AM
05:00AM
Nov-14-23 10:00AM
06:50AM Loading…
Oct-31-23 06:50AM
Oct-25-23 05:00PM
Sep-28-23 08:10PM
Sep-06-23 05:00PM
Aug-11-23 06:08AM
Aug-08-23 10:19PM
06:30AM
06:00AM
Jul-11-23 05:00PM
Jun-30-23 06:15AM
Jun-21-23 08:00PM
May-20-23 08:26AM
May-15-23 05:38PM
05:00PM
09:30AM
09:30AM
May-13-23 08:16AM
12:05AM
May-12-23 06:30AM
06:15AM
06:00AM
May-01-23 01:08PM
Apr-26-23 08:00PM
Apr-22-23 07:20AM
Apr-21-23 06:15PM
Apr-20-23 05:00PM
Mar-26-23 08:45AM
Mar-22-23 06:46AM
Mar-10-23 10:32AM
Feb-24-23 10:00AM
05:50AM
Feb-22-23 05:00PM
Feb-16-23 07:28AM
Feb-15-23 04:53PM
05:32AM
Feb-14-23 06:54PM
12:08PM
06:30AM
06:00AM
Feb-08-23 05:00PM
Jan-30-23 01:25PM
Jan-25-23 07:00AM
Jan-24-23 05:00PM
Jan-21-23 06:16PM
Dec-20-22 11:34AM
10:29AM
06:30AM
06:00AM
Dec-14-22 05:00PM
Nov-08-22 10:03AM
Nov-07-22 06:50AM
Nov-03-22 05:00PM
Nov-01-22 06:50AM
Sep-16-22 04:30PM
Sep-14-22 06:00AM
Aug-18-22 05:00PM
Aug-15-22 06:30AM
06:00AM
Aug-05-22 09:01AM
Jul-05-22 05:00PM
Jun-29-22 12:06PM
May-13-22 06:30AM
May-09-22 04:05PM
Apr-19-22 06:50AM
Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. Its products include pen needles, syringes, and safety devices complemented by a digital application. The company was founded in 1924 and is headquartered in Parsippany, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Melcher David FDirectorFeb 12 '24Buy16.252,00032,50045,080Feb 12 07:08 PM
Melcher David FDirectorSep 08 '23Buy15.776,23398,27127,698Sep 08 09:47 PM
Kurdikar DevdattPresident and CEOAug 10 '23Buy21.815,000109,050244,791Aug 10 05:11 PM
Mann Jeffrey ZSVP, GC, Head Corp. Dev., SecyAug 10 '23Buy21.674,700101,84955,333Aug 10 05:10 PM
Elguicze JacobSVP and CFOAug 10 '23Buy21.664,625100,19566,027Aug 10 05:09 PM